US2008193467A1PendingUtilityA1
Dendritic cell potentiation
Est. expiryJul 16, 2022(expired)· nominal 20-yr term from priority
C07K 14/4705A61K 38/00C07K 2317/74A61K 2039/505A61P 37/00C07K 14/70503C07K 14/465C07K 16/2827C07K 2317/21C07K 2317/52C07K 17/00Y10S424/808A61K 40/421A61K 40/24A61K 40/19A61K 40/11A61K 40/00A61K 39/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are compositions containing the molecule and methods for using the compositions to treat or immunize individuals.
Claims
exact text as granted — not AI-modified1 . A method of enhancing dendritic cell function in a mammal, said method comprising administering to said mammal in need thereof a composition comprising a purified molecule that binds to B7-DC polypeptides on a cell, wherein said binding results in cross-linking of a plurality of said B7-DC polypeptides, and wherein said molecule can potentiate an immune response upon administration to a mammal.
2 . The method of claim 1 , wherein said enhancing dendritic cell function involves prolonging the longevity of said dendritic cells.
3 . The method of claim 1 , wherein said molecule is an antibody.
4 . The method of claim 3 , wherein said antibody is an IgM antibody.
5 . The method of claim 4 , wherein said IgM antibody is sHIgM12.
6 . The method of claim 1 , wherein said mammal is a human.
7 . A method of potentiating an immune response in a mammal in need thereof, said method comprising administering to said mammal a composition comprising a purified molecule that binds to B7-DC polypeptides on a cell, wherein said binding results in cross-linking of a plurality of said B7-DC polypeptides, and wherein said molecule can potentiate an immune response upon administration to a mammal.
8 . The method of claim 7 , wherein said molecule is an antibody.
9 . The method of claim 8 , wherein said antibody is an IgM antibody.
10 . The method of claim 9 , wherein said IgM antibody is sHIgM12.
11 . The method of claim 7 , wherein said mammal is a human.
12 . A method of treating a tumor in a mammal, said method comprising administering to said mammal a composition comprising a purified molecule and an antigen, wherein said purified molecule binds to B7-DC polypeptides on a cell, wherein said binding results in cross-linking of a plurality of said B7-DC polypeptides, wherein said molecule can potentiate an immune response upon administration to a mammal, and wherein said antigen is capable of eliciting an immune response when said composition is administered to a mammal.
13 . The method of claim 12 , wherein said antigen is a tumor antigen.
14 . The method of claim 12 , wherein said mammal is a human.
15 . A method of inducing immunity to a pathogen in a mammal, said method comprising administering to said mammal a composition comprising a purified molecule and an antigen, wherein said purified molecule binds to B7-DC polypeptides on a cell, wherein said binding results in cross-linking of a plurality of said B7-DC polypeptides, wherein said molecule can potentiate an immune response upon administration to a mammal, wherein said antigen is capable of eliciting an immune response when said composition is administered to a mammal, and wherein said antigen is from a pathogen.
16 . The method of claim 15 , wherein said antigen is a component of a killed virus or a component of a killed bacterium.
17 . The method of claim 15 , wherein said antigen is a killed virus or a killed bacterium.
18 . The method of claim 15 , wherein said mammal is a human.
19 . A method of potentiating an immune response in a mammal in need thereof, said method comprising:
(a) contacting dendritic cells of said mammal in vitro with a composition comprising a purified molecule and an antigen, wherein said purified molecule binds to B7-DC polypeptides on a cell, wherein said binding results in cross-linking of a plurality of said B7-DC polypeptides, wherein said molecule can potentiate an immune response upon administration to a mammal, and wherein said antigen is capable of eliciting an immune response when said composition is administered to a mammal; and (b) transferring said contacted dendritic cells into said mammal.
20 . The method of claim 19 , wherein said mammal is a human.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.